Biogen Message Board - Msg: 11262848

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 172.61

+4.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Harold Engstrom who wrote (1128)	9/15/1999 5:45:00 PM
From: William Partmann	Read Replies (2) of 1686

Biogen sees Q3 above street's projections CAMBRIDGE, Mass., Sept 15 (Reuters) - Pharmaceutical company Biogen Inc. on Wednesday said it expects third-quarter earnings to be about $0.38 per share and revenues to be higher than expected because of continued growth in prescriptions for its multiple sclerosis drug Avonex. Analysts had expected the Biogen to earn $0.36 per share in the third quarter, according to First Call/Thomson. Third-quarter sales for Avonex are expected to reach about $160 million, the company said. Biogen's Avonex (Interferon beta-1a) is the world's leading therapy for treatment of relapsing forms of multiple sclerosis. Shares of Biogen Wednesday closed down 3-1/4 to 84-1/8 on the Nasdaq stock market before the news of the earnings projections was released.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next